Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy

Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.